Additionally, we found that TUBA1B+ TAMs, C1QC+ TAMs and IL1B+ TAMs were predominant in early-stage tumors, whereas VCAN+ TAMs, SLC40A1+ TAMs and APOC1+ TAMs had higher proportions in patients with advanced cancer. Here, C1QC is linked to cancer.